This post is from a suggested group
Precision Medicine Revolution: Exploring the Essential Role, Technological Integration, and Significant Growth Factors in the Global Companion Diagnostics for Oncology Market
The global Companion Diagnostics (CDx) for Oncology Market is an indispensable pillar of the precision medicine paradigm, enabling the critical identification of specific biomarkers that predict a patient’s likely response to a targeted therapeutic agent, thus optimizing treatment outcomes and minimizing unnecessary side effects. The market’s substantial growth is primarily driven by the rising global incidence of various cancers, coupled with the rapid development and regulatory approval of targeted cancer therapies, many of which necessitate a corresponding CDx test for clinical use. The co-development of a drug and its diagnostic companion ensures that the right patient receives the right drug at the right dose, which is becoming the gold standard in modern oncology practice. Segmentation by technology reveals a dynamic environment, with traditional Polymerase Chain Reaction (PCR) and Immunohistochemistry…